Preclinical data show potential effectiveness of CRISPR Therapeutics’ off-the-shelf CAR-T cells; shares up 2% after … – Seeking Alpha
|
Preclinical data show potential effectiveness of CRISPR Therapeutics’ off-the-shelf CAR–T cells; shares up 2% after …
Seeking Alpha Gene editor CRISPR Therapeutics (NASDAQ:CRSP) is up 2% after hours on modest volume on the heels of its announcement of encouraging preclinical data supporting the potential efficacy of its off-the-shelf CAR-T candidates. The results were presented at … |
Fortune |
Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer
Fortune New study results released Monday continue to cement drug giant Merck’s status as the force to be reckoned with in the lung cancer treatment space. Merck’s flagship cancer immunotherapy Keytruda (or pembrolizumab), combined with chemotherapy, helped … Merck BMS Roche lung cancer immunotherapy data – Business InsiderBusiness Insider Merck lung cancer trial boosts immunotherapy hopes – Financial TimesFinancial Times Merck, Bristol-Myers immunotherapies impress in key lung cancer …Reuters WHTC –Zacks all 76 news articles » |
Scope (blog) |
Altered immune cells clear childhood brain tumor in mice
Science Daily To begin the research, the scientists screened human DIPG tumor cultures for surface molecules that could act as targets for CAR–T cells. In CAR-T therapies now used in humans, some of the patient’s own immune cells are removed, engineered to attack a … Engineered immune cells clear deadly pediatric brain tumor in miceScope (blog) |